116 patents
Page 4 of 6
Utility
Engineering Wheat with Increased Dietary Fiber
18 Mar 21
Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).
Nicholas BALTES, Javier GIL HUMANES
Filed: 2 May 19
Utility
Plants for Production of Therapeutic Proteins
4 Mar 21
Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.
Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
Filed: 13 Nov 20
Utility
CD19 Specific Chimeric Antigen Receptor and Uses Thereof
4 Mar 21
The present invention relates to chimeric antigen receptors (CAR).
Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
Filed: 16 Nov 20
Utility
CD19 Specific Chimeric Antigen Receptor and Uses Thereof
4 Mar 21
The present invention relates to chimeric antigen receptors (CAR).
Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
Filed: 16 Nov 20
Utility
Tale-nucleases for Allele-specific Codon Modification and Multiplexing
21 Jan 21
The present invention relates to the field of genome engineering (gene editing).
Alex BOYNE, Brian BUSSER, Philippe DUCHATEAU, Aymeric DUCLERT
Filed: 29 Mar 19
Utility
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
19 Jan 21
The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer.
Julien Valton, Veronique Zennou, Philippe Duchateau, Laurent Poirot
Filed: 13 Apr 17
Utility
CorrectedCD19 Specific Chimeric Antigen Receptor and Uses Thereof
6 Jan 21
The present invention relates to chimeric antigen receptors (CAR).
Roman Galetto, Julianne SMITH, Andrew SCHARENBERG, Cecile SCHIFFER-MANNIOUI
Filed: 25 Mar 19
Utility
Methods for Non-transgenic Genome Editing In Plants
6 Jan 21
Materials and methods for creating genome-engineered plants with non-transgenic methods are provided herein.
Daniel F. Voytas, Feng Zhang, Jin Li, Thomas Stoddard, Song Luo
Filed: 15 Sep 20
Utility
Cells for Immunotherapy Engineered for Targeting Antigen Present Both on Immune Cells and Pathological Cells
30 Dec 20
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Philippe DUCHATEAU, Laurent POIROT
Filed: 26 Jul 20
Utility
Trophoblast Glycoprotein (5T4, TPBG) Specific Chimeric Antigen Receptors for Cancer Immunotherapy
30 Dec 20
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells.
Cecile Schiffer-Mannioui
Filed: 23 Jul 20
Utility
Targeted Gene Integration of CRS Inhibitor Genes for Improved Immune Cells Therapy
30 Dec 20
The invention pertains to the field of adaptive cell immunotherapy.
Brian BUSSER, Philippe DUCHATEAU, Alexandre JUILLERAT, Laurent POIROT, Julien VALTON, Mohit SACHDEVA
Filed: 15 Apr 18
Utility
CD19 specific chimeric antigen receptor and uses thereof
28 Dec 20
The present invention relates to chimeric antigen receptors (CAR).
Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
Filed: 11 May 14
Utility
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
21 Dec 20
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe Duchateau, André Choulika, Laurent Poirot
Filed: 17 Feb 20
Utility
New Sequence Specific Reagents Targeting CCR5 In Primary Hematopoietic Cells
16 Dec 20
The invention pertains to the field of cell therapy and HIV treatments.
Toni CATHOMEN, Tatjana CORNU, Philippe DUCHATEAU, Claudio MUSSOLINO, Marianna ROMITO, Agnes GOUBLE
Filed: 12 Apr 18
Utility
Method for Generating Immune Cells Resistant to Arginine And/or Tryptophan Depleted Microenvironment
9 Dec 20
The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy.
Laurent Poirot, Mathieu Simon
Filed: 12 Aug 20
Utility
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
16 Nov 20
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Philippe Duchateau, Laurent Poirot
Filed: 12 Feb 15
Utility
Modifying messenger RNA stability in plant transformations
16 Nov 20
Materials and methods for genome engineering through transient expression of a targeted nuclease are described herein.
Thomas Stoddard, Song Luo
Filed: 28 Feb 16
Utility
Method of engineering chemotherapy drug resistant T-cells for immunotherapy
26 Oct 20
The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer.
Julien Valton, Philippe Duchateau, David Sourdive
Filed: 20 Nov 14
Utility
Transcription activator-like effector (TALE) fusion protein
26 Oct 20
The present invention relates to Transcription Activator-Like Effector (TALE) derived proteins that allow efficient targeting and/or processing of double stranded nucleic acid sequences.
Alexandre Juillerat, Philippe Duchateau
Filed: 4 Jun 13
Utility
Method for Improving Production of Car T Cells
21 Oct 20
A method for engineering less alloreactive immune cells, including T-cells that express chimeric antigen receptors (CARs), using a nucleotide sequence in form of an RNA encoding a anti-TCR CAR to achieve the transient expression of anti-TCR CAR at the cell surface.
Alex BOYNE, Laurent POIROT, Philippe DUCHATEAU, Alexandre JUILLERAT
Filed: 27 Dec 18